

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102401 A1

(51) International Patent Classification⁷: A61K 38/09,
A61P 25/28

(81) Designated States (*national*): AU, BG, BR, BY, CA, CN,
CO, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ,
LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA,
UZ, YU, ZA.

(21) International Application Number: PCT/EP02/04677

(22) International Filing Date: 27 April 2002 (27.04.2002)

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(25) Filing Language: English

(26) Publication Language: English

Published:
— with international search report

(30) Priority Data:
60/287,434 30 April 2001 (30.04.2001) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant: ZENTARIS AG [DE/DE]; Weismüllerstrasse
45, 60314 Frankfurt (DE).

(72) Inventors: ENGEL, Jürgen; Erlenweg 3, 63755
Alzenau (DE). VOEGELI, Rainer; Am Berg 4, 63599
Biebergemünd-Bieber (DE).



WO 02/102401 A1

(54) Title: TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISEASES WITH INTERMEDIATE DOSES OF LHRH ANTAGONISTS

(57) Abstract: The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetorelix.

Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists

The present invention relates to the treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists which do not cause a castration.

FURUYA, Shuichi et al. in WO 01/78780 teach preventives and remedies for Alzheimer's disease containing a compound having GnRH antagonism have effects of preventing and treating Alzheimer's disease with little toxicity.

It has been shown in a study by Bowen R.L et al. that serum concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were significantly higher in individuals suffering of dementia, e.g. Alzheimer's disease. Bowen R.L. et al. propose in their patent application CA 2,309,395 (US priority June 4, 1999, 09/326,180) to lower FSH and LH to minimal levels by the use of castrating doses of analogues of the LH-releasing hormone (LHRH), either super-agonists or antagonists.

This treatment would be accompanied by highly undesirable side effects as lowering sex hormone levels to castration levels would result in loss or reduction of libido, sexual desire and sexual potency. In men and pre-menopausal women this treatment would also result in the typical symptoms of drop of sex hormones like hot flushes, etc. Women would additionally suffer from loss of bone minerals that would limit the treatment.

These side effects could be reduced by hormone replacement therapy.

It has been found now that the treatment with intermediate doses of LHRH antagonists results in a sub-maximal lowering of FSH and LH to normal levels that leaves sex hormone levels above the castration threshold.

This treatment is highly advantageous as it gives the desired results of normalising FSH and LH levels without the undesirable side-effects of sex hormone blockade. Thus the additional treatment of sex hormone replacement becomes superfluous.

The present invention relates to the treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists, wherein the antagonist is preferably cetorelix, teverelix, antide or abarelix. The antagonist can also be the LHRH antagonist D-63 153 (Ac-D-Nal-D-pCl-Phe-D-Pal-Ser-N-Me-Tyr-D-Hci-Nle-Arg-Pro-D-Ala-NH₂) as described in the PCT application WO 00/55190 A1.

The mentioned LHRH antagonists can also exhibit a heterocyclic skeletal structure. Such peptidomimetics can be for example

- 1-[7-Chloro-3-(3,5-dimethyl-phenyl)-2-oxo-4-(2-piperidin-2-yl-ethoxy)-1,2-dihydro-quinolin-6-yl]-3-pyridin-2-yl-urea (described in WO 97/44339),
- 3-[Benzyl-methyl-amino)-methyl]-2-*tert*-butyl-8-(2-fluoro-benzyl)-6-(3-methoxy-phenyl)-7-methyl-8*H*-imidazo[1,2-a]pyrimidin-5-one (described in WO 01/29044),
- 2-(2,5-Dimethyl-furan-3-yl)-8-(2-fluoro-benzyl)-3-([methyl-(2-pyridin-2-yl-ethyl)-amino]-methyl)-5-oxo-5,8-dihydro-imidazo[1,2-a]pyrimidine-6-carboxylic acid 1-ethyl-propylester (described in WO 00/69859),
- 3-((2-[2-(3,5-Difluoro-phenyl)-1-(2-methoxy-benzoyl)-2-oxo-ethylidene]-2,3-dihydro-1*H*-benzoimidazol-5-yl-amino)-methyl)-benzonitrile (described in WO 02/02533).

The LHRH antagonist is given in a monthly dose of 10 to 100 mg per month and the treatment is repeated monthly, two-monthly or lasting several months.

In a preferred embodiment the LHRH antagonist is given in a monthly dose of 30 to 60 mg per month and the treatment is repeated monthly, two-monthly or lasting several months.

Pharmaceutical formulations of the LHRH antagonist suitable for the therapeutic management of dementia and neurodegenerative diseases may be for example

- a) acetate salt formulations of the active compounds in the concentration of 1 mg/1 ml or lower where the lyophilisate powder may be dissolved in water for injection or in gluconic acid;
- b) acetate salt formulations of the active compounds in the concentration of 1.5 mg/1 ml to 5.0 mg/1 ml, preferably 2.5 mg/1 ml where the lyophilisate powder may be dissolved in water for injection or in gluconic acid;
- c) pamoate salt formulations of the active compounds in the concentration of 10 mg/1 ml to 30 mg/1 ml, preferably 15 mg/1 ml where the lyophilisate powder may be dissolved in gluconic acid or in water for injection.

Suitable excipients and dosage forms are for example described by K.H. Bauer, K.-H. Frömming and C. Führer, Lehrbuch der Pharmazeutischen Technologie, 6th edition, Stuttgart 1999, pages 163-186 (excipients) and pages 227-386 (dosage forms), including the references as cited therein.

The LHRH antagonist can be administered for example subcutaneous, oral, intramuscular or inhalative.

The disease as mentioned, for example can be treated in accordance with the following scheme.

Example

In one embodiment of the invention a single dose of 30-60 mg of cetrorelix is administered by injection per month. The treatment is continued monthly. In another embodiment the treatment is continued two-monthly or lasting several months after the administration of the single dose.

Claims

1. Use of a LHRH antagonist for the preparation of a medicament for the treatment of dementia and neurodegenerative diseases in humans by administration of intermediate doses, which do not cause a castration.
2. Use according to claim 1, characterized in that the monthly single dose is in the range of 10 – 100 mg LHRH antagonist.
3. Use according to claims 1 and 2, characterized in that the monthly single dose is about 30 to about 60 mg LHRH antagonist.
4. Use according to one of claims 1 to 3, characterized in that the administration is continued on a monthly or two-monthly or lasting several months base.
5. Use according to one of claims 1 to 4, characterized in that the treated disease is Alzheimer's disease.
6. Use according to one of claims 1 to 5, characterized in that the LHRH antagonist is cetrorelix.
7. Use according to one of claims 1 to 5, characterized in that the LHRH antagonist is teverelix.
8. Use according to one of claims 1 to 5, characterized in that the LHRH antagonist is antide.
9. Use according to one of claims 1 to 5, characterized in that the LHRH antagonist is abarelix.

10. Use according to one of claims 1 to 5, characterized in that the LHRH antagonist is D-63 153 (Ac-D-Nal-D-pCl-Phe-D-Pal-Ser-N-Me-Tyr-D-Hci-Nle-Arg-Pro-D-Ala-NH₂).
11. Use according to one of claims 1 to 5, characterized in that the LHRH antagonist is a peptidomimetic.
12. Use according to claim 11 in which the peptidomimetic is a compound
- 1-[7-Chloro-3-(3,5-dimethyl-phenyl)-2-oxo-4-(2-piperidin-2-yl-ethoxy)-1,2-dihydro-quinolin-6-yl]-3-pyridin-2-yl-urea
 - 3-[Benzyl-methyl-amino)-methyl]-2-*tert*-butyl-8-(2-fluoro-benzyl)-6-(3-methoxy-phenyl)-7-methyl-8*H*-imidazo[1,2-*a*]pyrimidin-5-one
 - 2-(2,5-Dimethyl-furan-3-yl)-8-(2-fluoro-benzyl)-3-([methyl-(2-pyridin-2-yl-ethyl)-amino]-methyl)-5-oxo-5,8-dihydro-imidazo[1,2-*a*]pyrimidine-6-carboxylic acid 1-ethyl-propylester or
 - 3-((2-[2-(3,5-Difluoro-phenyl)-1-(2-methoxy-benzoyl)-2-oxo-ethylidene]-2,3-dihydro-1*H*-benzoimidazol-5-yl-amino)-methyl)-benzonitrile.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/04677

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/09 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, CHEM ABS Data, BIOSIS, PHARMAPROJECTS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CA 2 309 395 A (BOWEN RICHARD LLOYD) 4 December 2000 (2000-12-04)	1
Y	page 10, line 10 - line 20 page 11, line 26 - page 12, line 10 page 12, line 15	1-12
Y	WO 00 55190 A (ASTA MEDICA AG) 21 September 2000 (2000-09-21) cited in the application claim 4	1-10
Y	WO 97 44339 A (GOULET MARK ;JIANG JINLONG (US); ALLEN ERIC E (US); DEVITA ROBERT) 27 November 1997 (1997-11-27) cited in the application example 1	1-12
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

2 August 2002

Date of mailing of the international search report

28/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Giacobbe, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/04677

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 29044 A (CHEN CHEN ;ZHU YUN FEI (US); GAO YINGHONG (US); GROSS TIMOTHY D (U) 26 April 2001 (2001-04-26) cited in the application claim 25	1-12
Y	WO 00 69859 A (STRUTHERS R SCOTT ;CHEN CHEN (US); TUCCI FABIO C (US); ZHU YUN FEI) 23 November 2000 (2000-11-23) cited in the application claim 30	1-12
P,Y	WO 02 02533 A (MORITOMO HIROYUKI ;HIRANO MASAOKI (JP); KAWAMINAMI EIJI (JP); OKAD) 10 January 2002 (2002-01-10) cited in the application the whole document	1-12

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/EP 02/04677

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
CA 2309395	A	04-12-2000	US 6242421 B1 CA 2309395 A1	05-06-2001 04-12-2000
WO 0055190	A	21-09-2000	DE 19911771 A1 AU 3288700 A BR 0009472 A CN 1348462 T CZ 20013318 A3 WO 0055190 A1 EP 1163264 A1 NO 20014486 A TR 200103339 T2	28-09-2000 04-10-2000 27-11-2001 08-05-2002 15-05-2002 21-09-2000 19-12-2001 02-11-2001 22-04-2002
WO 9744339	A	27-11-1997	AU 710926 B2 AU 3008997 A CA 2254769 A1 EP 0901489 A1 JP 2000511532 T WO 9744339 A1 US 6150352 A ZA 9704321 A	30-09-1999 09-12-1997 27-11-1997 17-03-1999 05-09-2000 27-11-1997 21-11-2000 20-11-1997
WO 0129044	A	26-04-2001	AU 1208901 A EP 1220857 A1 WO 0129044 A1	30-04-2001 10-07-2002 26-04-2001
WO 0069859	A	23-11-2000	AU 4845700 A EP 1185530 A1 WO 0069859 A1	05-12-2000 13-03-2002 23-11-2000
WO 0202533	A	10-01-2002	AU 7102201 A WO 0202533 A1	14-01-2002 10-01-2002

THIS PAGE BLANK (USPTO)